ARTAN Bio Closes $1 Million Seed Round to Advance its tRNA Platform Toward Human Studies

Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biology. ST. PETERSBURG, ...
The Scientist

Getting rid of nonsense

Many human diseases are caused by point mutations that affect RNA splicing. It has been observed that nonsense mutations that generate premature termination of translation products can drive the use ...
Monthly Prescribing Reference

FDA Accepts Resubmitted Translarna NDA for Nonsense Mutation DMD

In Study 041, Translarna showed a significant improvement in six key study endpoints compared with placebo after 72 weeks. The Food and Drug Administration (FDA) has accepted for review the ...
The Scientist

The Origins and Recent Promise of Nonsense Suppressor tRNAs

Between 10 to 15% of all genetic diseases have the same underlying cause: a nonsense mutation. 1 This type of mutation results from a stop codon in the middle of a gene sequence, which terminates ...